Cannabis UserCANNABEXNCT06081218
Effect of Acute Exercise on Cognitive Functions and Blood Markers of Brain Plasticity in Regular Chronic Cannabis Users
A study testing activity test in people with Cannabis User, run by University Hospital, Lille at 1 site in France.
Trial summary
The endocannabinoid system (ECS) is a complex endogenous signaling system made up of transmembrane cannabinoid receptors (CB1 and CB2 receptors), their endogenous lipid-derived ligands (the endocannabinoids - eCBs), and enzymes for ligand biosynthesis and degradation. Read more about this study
- Who is it for?
- Ages 18 to 35 yearsHealthy volunteers can take part
- Conditions the study is for
- Cannabis User
- What is being tested?
- activity test
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 60 participants
- Where
- 1 siteFrance
- Study dates
- 7 May 2024to 31 Dec 2029
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 35 years
- All sexes
- Healthy volunteers accepted
- Adult
Who may be able to join
- Cannabis consumer group:
- Cannabis consumption > 100 times in lifetime, last exposure < 7 days, and recent exposure > 10 times in the month.
- Positive toxicological urine test for ∆-9-THC.
- Having a cannabis use disorder according to the CAST.
- Healthy group:
- Negative urine toxicological test for cannabis.
- No regular cannabis use for more than 6 months once in a lifetime.
- No cannabis consumption in the 6 months preceding the study.
Who cannot join
- For all subjects :
- Disorders of use of other substances (alcohol, cocaine, opioid, or synthetic drugs).
- Alcohol consumption greater than 30g per day (averaged over one week) and/or alcohol abuse the week preceding the visit.
- Under medical treatment.
- Presence of diagnosed neurological disorders.
- Diagnosis of a psychotic picture entering axis I, DSM-5.
- Chronic progressive disease or in remission.
- Body mass index > 30 kg/m2 (i.e. presence of obesity).
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
France1 site, 1 recruiting
- Recruiting
CHU Lille
Lille, 59000
COTTENCIN Olivier, Olivier.COTTENCIN@chu-lille.fr
GAMELIN François-Xavier, PhD, 06.26.19.23.09, francois-xavier.gamelin@univ-lille.fr
About this study
The endocannabinoid system (ECS) is a complex endogenous signaling system made up of transmembrane cannabinoid receptors (CB1 and CB2 receptors), their endogenous lipid-derived ligands (the endocannabinoids - eCBs), and enzymes for ligand biosynthesis and degradation. Interestingly, exercise increase plasma AEA, one of the most famous endocannabinoid. This increase could be involved in exercise-induced neurogenesis and other beneficial exercise adaptations. Chronic cannabis use is associated with alteration of ECS activity. The aim of the study is to compare ECS response to exercise between chronic cannabis users and non-users.
- Conditions
- Cannabis User
- Being tested
- activity test
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
activity testOther
Over 2 weeks, participants have to do a maximal progressive exercise and a 30 min constant exercise at 50% of maximal aerobic power
| Study group | Role | What they receive |
|---|---|---|
| Chronic cannabis users | Experimental | Not described Receives: Other: activity test |
| Healthy subjects | Sham comparator | Not described Receives: Other: activity test |
What is being measured
The primary outcome is the main question the study is designed to answer.
Plasma endocannabinoids levels (pmol/ml)
Measured: 2 weeks
Secondary outcomes (5)
regulating hormone of endocannabinoids (plasma levels of cortisol, ng/ml)
Measured: 2 weeks
Blood marker of neurogenesis and neuroplasticity (plasma levels and BDNF, pg/ml)
Measured: 2 weeks
change in cerebral muscular, oxygenation (HHB), (HbO2), (Hbtot) (arbitrary unit)
Measured: 2 weeks
Cognitive function (selective attention, stroop test)
The stroop test can be used to measure a person's selective attention capacity
Measured: 2 weeks
Oxygen consumption (VO2) (ml/min/kg)
Measured: 2 weeks
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted13 Oct 2023
- Study start7 May 2024
- Primary completion31 May 2029 (estimated)
- Study completion31 Dec 2029 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Cannabis UserStudies of the same condition, open and under way.
- More trials run by University Hospital, LilleThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Other
- Allocation
- Non-randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Enrolment
- 60 participants (estimated)
Sponsor and investigators
- Lead sponsor
- University Hospital, Lille
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06081218
- Sponsor's protocol ID
- 2016_70
- Acronym
- CANNABEX
- Status last verified
- May 2026
- First submitted
- 6 Jul 2023
- Last updated
- 15 May 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 15 May 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Effect of Acute Exercise on Cognitive Functions and Blood Markers of Brain Plasticity in Regular Chronic Cannabis Users
- ClinicalTrials.gov ID
- NCT06081218
- Acronym / sponsor ID
- CANNABEX / 2016_70
- Conditions
- Cannabis User
- Study type
- Interventional
- Recruitment status
- Recruiting
- Enrolment
- 60 participants (estimated)
- Lead sponsor
- University Hospital, LilleUniversity, hospital or other
- Study start
- 7 May 2024 (actual)
- Primary completion
- 31 May 2029 (estimated)
- Study completion
- 31 Dec 2029 (estimated)
- First posted
- 13 Oct 2023 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The endocannabinoid system (ECS) is a complex endogenous signaling system made up of transmembrane cannabinoid receptors (CB1 and CB2 receptors), their endogenous lipid-derived ligands (the endocannabinoids - eCBs), and enzymes for ligand biosynthesis and degradation. Interestingly, exercise increase plasma AEA, one of the most famous endocannabinoid. This increase could be involved in exercise-induced neurogenesis and other beneficial exercise adaptations. Chronic cannabis use is associated with alteration of ECS activity. The aim of the study is to compare ECS response to exercise between chronic cannabis users and non-users.
Study design
- Primary purpose
- Other
- Allocation
- Non-randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Chronic cannabis users | Experimental | Other: activity test |
| Healthy subjects | Sham comparator | Other: activity test |
Who may qualify
- Ages
- 18 to 35 years
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult
Key inclusion criteria (8 listed)
- Cannabis consumption > 100 times in lifetime, last exposure < 7 days, and recent exposure > 10 times in the month.
- Positive toxicological urine test for ∆-9-THC.
- Having a cannabis use disorder according to the CAST.
- Negative urine toxicological test for cannabis.
- No regular cannabis use for more than 6 months once in a lifetime.
Key exclusion criteria (8 listed)
- Disorders of use of other substances (alcohol, cocaine, opioid, or synthetic drugs).
- Alcohol consumption greater than 30g per day (averaged over one week) and/or alcohol abuse the week preceding the visit.
- Under medical treatment.
- Presence of diagnosed neurological disorders.
- Diagnosis of a psychotic picture entering axis I, DSM-5.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| activity testOver 2 weeks, participants have to do a maximal progressive exercise and a 30 min constant exercise at 50% of maximal aerobic power | Other | Chronic cannabis users, Healthy subjects |
Primary outcome
Plasma endocannabinoids levels (pmol/ml)
Time frame: 2 weeks
5 secondary outcomes
regulating hormone of endocannabinoids (plasma levels of cortisol, ng/ml)
Time frame: 2 weeks
Blood marker of neurogenesis and neuroplasticity (plasma levels and BDNF, pg/ml)
Time frame: 2 weeks
change in cerebral muscular, oxygenation (HHB), (HbO2), (Hbtot) (arbitrary unit)
Time frame: 2 weeks
Cognitive function (selective attention, stroop test)
Time frame: 2 weeks
Oxygen consumption (VO2) (ml/min/kg)
Time frame: 2 weeks
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 15 May 2026.
Related trials for Cannabis User
Active, not recruiting
Evaluation of a Brief Computerized and Smart Phone-based Intervention for Stress in Regular Cannabis Users
Cannabis Use Disorder
RecruitingEarly Phase 1
Repeated CBD Administration and Cannabis Outcomes
Cannabis, Abuse Liability
Recruiting
Medical Cannabis and Behavior
Chronic Pain Patients, Medical Cannabis Users
Recruiting
Transcranial Magnetic Brain Stimulation to Reduce Cannabis Use in Heavy Cannabis Users
Cannabis
Recruiting
Neuroimaging of Adolescent Cannabis Use Treatment
Cannabis Use, Cannabis Dependence
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing activity test in people with Cannabis User, run by University Hospital, Lille at 1 site in France.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 8 inclusion and 8 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 15 May 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in France. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Olivier Cottencin, MD,PhD (0320445962, olivier.cottencin@chru-lille.fr), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Plasma endocannabinoids levels (pmol/ml) (time frame: 2 weeks). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 15 May 2026.